Completed PHASE2 INTERVENTIONAL 1-arm NCT00080262

Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

Phase II Study of Novel Epothilone (BMS-247550) in Patients With MBC Who Are Refractory to an Anthracycline, a Taxane, and Capecitabine

Sponsor: R-Pharm

Conditions Breast Cancer Metastases

Interventions Ixabepilone

Updated 7 times since 2017 Last updated: Jan 27, 2017 Started: Feb 29, 2004 Primary completion: Dec 31, 2006 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Breast Cancer and Metastases and is currently completed. R-Pharm leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

R-Pharm

Data source: R-Pharm

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Asheville, United States , Baltimore, United States , Besançon, France , Bobigny, France , Boston, United States , Buenos Aires, Argentina , Charlotte, United States , Chattanooga, United States , Chihuahua City, Mexico and 35 more locations